UNSPSC 51182073: Testosterone hexahydrobenzoate

This classification denotes an androgen with the molecular formula C26H38O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T4QOX8847Z, chemically known as androst-4-en-3-one, 17-((cyclohexylcarbonyl)oxy)-, (17.beta.)-, but more generally known as testosterone hexahydrobenzoate, which bears US NIH Compound Identifier 85694. European Medicines Agency schedules testosterone hexahydrobenzoate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10937MIG.

Most nations, for tariff purposes, schedule testosterone hexahydrobenzoate under HS 29372900. SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2OC(=O)C4CCCCC4)CCC5=CC(=O)CC[C@]35C.

UNSPSC 51182073 Testosterone hexahydrobenzoate is a Commodity code encompassing pharmaceutical active ingredients and finished pharmaceutical products that state and local government facilities procure through cooperative purchasing vehicles. Based on recent solicitation activity, state and local governments buy this code as part of comprehensive generic multi-source pharmaceutical procurement programs that supply hospitals, clinics, correctional facilities, and other public health infrastructure. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, dominates recent activity under this code, establishing master agreements with manufacturers and branded distributors to supply generic pharmaceuticals and over-the-counter products across participating state and local facilities in Minnesota, Oregon, and other member jurisdictions. Vendors responding to such solicitations must hold current Good Manufacturing Practices (cGMP) certification and comply with Drug Supply Chain Security Act (DSCSA) requirements, maintain contractual relationships with authorized pharmaceutical wholesalers (such as AmerisourceBergen, Cardinal Health, and Morris & Dickson), and carry comprehensive insurance including $5 million commercial general liability coverage per occurrence.

MMCAP's Request for Proposal S1070000015802, posted January 20, 2026 with a response deadline of March 26, 2026, exemplifies the scope of work under this code. The solicitation establishes multiple contracts for generic pharmaceuticals with specific National Drug Codes (NDC), requiring vendors to submit detailed product information, NDC codes, SKUs, UPCs, dosage forms, packaging configurations, and manufacturing locations. Award decisions are weighted heavily toward price competitiveness (75 percent), with remaining points allocated to fixed pricing terms, administrative fee compliance, EDI capability, and agreement to a 3 percent administrative fee. The contract term runs two years for new responders with optional extensions, with awarded vendors effective July 1, 2026. MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations and member-specific needs, and the RFP does not identify set-aside restrictions or disadvantaged-enterprise designations.